Cystic fibrosis transmembrane conductance-regulator modulators for children

Affiliations

¹ Cystic Fibrosis Centre, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, 20122 Milan, Italy. Electronic address: carla.colombo@unimi.it.

Comment

Carla Colombo. Lancet Respir Med. 2017 Jul.

. 2017 Jul;5(7):536-537.

doi: 10.1016/S2213-2600(17)30208-4. Epub 2017 Jun 9.

¹ Cystic Fibrosis Centre, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, 20122 Milan, Italy. Electronic address: carla.colombo@unimi.it.

No abstract available

Comment on

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group. Ratjen F, et al. Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Lancet Respir Med. 2017. PMID: 28606620 Clinical Trial.